Expanding Canada‑EU Medicine Trade Rules to Cover Active Ingredients

Summary

• The European Commission proposes that the EU Council adopt a position in the CETA Joint Committee to include active pharmaceutical ingredients (APIs) as medicinal products in the GMP Protocol (the protocol that recognises good manufacturing practices for drugs).
• CETA (Comprehensive Economic and Trade Agreement) was signed on 30 October 2016 and has been provisionally applied since 21 September 2017.
• The GMP Protocol is part of CETA and aims to make it easier for medicines and drugs to be traded between Canada and the EU by recognising each other’s GMP certificates.
• The Joint Committee, set up under Article 26.1 of CETA, can agree on amendments to the protocol.
• In 2018 Canada asked to be recognised as a country that protects public health for active substances exported to the EU.
• The Commission reviewed Canada’s system, did an on‑site audit in June 2022, and in January 2023 amended the list of recognised third countries to include Canada.
• Health Canada also assessed EU authorities and confirmed that the two systems are equivalent.
• On 15 December 2022 the Joint Sectoral Group (a sub‑group of the Joint Committee) recommended that APIs be added to the operational scope of the GMP Protocol.
• The proposed decision will support that recommendation, making the inclusion of APIs binding under international law once Canada completes its internal procedures.
• The legal basis for the decision is Article 218(9) of the Treaty on the Functioning of the European Union (TFEU) and Article 207(4) TFEU.
• The decision will be published in the Official Journal of the European Union after it is adopted.
• The draft decision (to be adopted by the Joint Committee) will amend Annex 1 of the GMP Protocol by adding “(h) active pharmaceutical ingredients.” and will enter into force on the first day of the second month after Canada notifies the EU that it has finished its internal requirements.

Broader context

This proposal sits inside the EU–Canada trade agreement known as CETA, which is not only about tariffs but also about how regulators cooperate. In pharmaceuticals, both sides try to ensure that medicines are manufactured under equivalent “Good Manufacturing Practice” (GMP) rules, meaning factories must meet strict safety and quality standards.

The GMP Mutual Recognition Agreement under CETA allows the EU and Canada to accept each other’s inspections and certificates instead of duplicating checks. That reduces administrative burden and speeds up trade in medicines.

The key change here is the expansion of that system to explicitly include active pharmaceutical ingredients (APIs). APIs are the core chemical components that make a medicine work (for example, the substance in a painkiller that actually reduces pain). Historically, GMP cooperation focused more on finished medicines. This update reflects that modern pharmaceutical supply chains are global: APIs are often produced in one country and turned into final medicines in another.

So the broader goal is to keep regulatory oversight strict while making cross-border pharmaceutical production more efficient and consistent between the EU and Canada.

Impact on people living in the EU

For most people in the EU, this change is not directly visible in daily life, but it can affect medicine supply chains in several indirect ways:

• More stable medicine availability: Easier trade in APIs can reduce delays or bottlenecks when medicines depend on ingredients manufactured in Canada or vice versa.
• Potential cost efficiency: Removing duplicate inspections can slightly reduce regulatory costs for companies, which can help limit price pressures on some medicines.
• Maintained safety standards: The change does not lower safety requirements. It is based on mutual recognition, meaning both sides must consider each other’s inspection systems equivalent.
• Faster regulatory cooperation: If a safety issue arises in a manufacturing site, coordinated oversight between EU and Canadian regulators can be quicker.

In short, the main effect is smoother and more efficient production and supply of medicines, while keeping the same level of quality control.

Impact on Canada

For Canada, the same system applies in reverse. Canadian regulators and manufacturers gain easier access to the EU market for pharmaceuticals that rely on compliant GMP certification, including APIs. This supports pharmaceutical trade and can strengthen integration between the two markets without changing core safety requirements.

What this does not change

• It does not change what medicines are approved for use in the EU.
• It does not reduce testing or safety standards for patients.
• It does not automatically approve any specific drug or ingredient for sale; it only affects manufacturing oversight and recognition between regulators.